Kidney Biopsy Findings in People With Metabolic Dysfunction-Associated Steatohepatitis.
作者信息
Pasternak Evgeniya, Larsen Christopher, Caza Tiffany
机构信息
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Arkana Laboratories, Little Rock, Arkansas, USA.
出版信息
Kidney Int Rep. 2025 Feb 17;10(5):1575-1578. doi: 10.1016/j.ekir.2025.02.008. eCollection 2025 May.
Abstract
摘要
相似文献
1
Kidney Biopsy Findings in People With Metabolic Dysfunction-Associated Steatohepatitis.代谢功能障碍相关脂肪性肝炎患者的肾活检结果
Kidney Int Rep. 2025 Feb 17;10(5):1575-1578. doi: 10.1016/j.ekir.2025.02.008. eCollection 2025 May.
2
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
3
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.代谢功能障碍相关脂肪性肝病增加慢性乙型肝炎患者不良结局的风险。
JHEP Rep. 2021 Aug 8;3(5):100350. doi: 10.1016/j.jhepr.2021.100350. eCollection 2021 Oct.
4
Noninvasive identification of metabolic dysfunction-associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study.代谢功能障碍相关脂肪性肝炎的非侵入性识别（INFORM MASH）：一项回顾性队列和疾病建模研究。
Expert Rev Gastroenterol Hepatol. 2025 Apr;19(4):427-435. doi: 10.1080/17474124.2025.2477249. Epub 2025 Mar 21.
5
Increased Renal Expression of Complement Components in Patients With Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination.肝脏疾病患者肾脏补体成分表达增加：非酒精性脂肪性肝炎、酒精相关、病毒性肝炎和酒精-病毒联合。
Toxicol Sci. 2022 Aug 25;189(1):62-72. doi: 10.1093/toxsci/kfac070.
6
Determinants of non-diabetic kidney diseases in type 2 diabetic patients: Twenty years of single center experience.2 型糖尿病患者中非糖尿病性肾脏疾病的决定因素：单中心 20 年经验。
Clin Nephrol. 2024 May;101(5):207-221. doi: 10.5414/CN111093.
7
Prediction of decreased estimated glomerular filtration rate using liver fibrosis markers: a renal biopsy-based study.使用肝纤维化标志物预测估算肾小球滤过率下降：一项基于肾活检的研究。
Sci Rep. 2022 Oct 21;12(1):17630. doi: 10.1038/s41598-022-22636-9.
8
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.代谢功能障碍相关脂肪性肝病相关肝肿瘤的病理学与发病机制
Biomedicines. 2023 Oct 12;11(10):2761. doi: 10.3390/biomedicines11102761.
9
Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.经活检证实的脂肪性肝病和脂肪性肝炎患者的循环激素：一项多中心观察性研究。
Metabolism. 2023 Nov;148:155694. doi: 10.1016/j.metabol.2023.155694. Epub 2023 Sep 25.
10
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.代谢相关脂肪性肝病时代非侵入性评分和血清生物标志物在脂肪性肝病中的应用：从非酒精性脂肪性肝病到代谢相关脂肪性肝病和脂肪性肝病的综合评价。
Curr Obes Rep. 2024 Sep;13(3):510-531. doi: 10.1007/s13679-024-00574-z. Epub 2024 May 29.
本文引用的文献
1
Secondary IgA nephropathy.继发性 IgA 肾病。
Kidney Int. 2018 Oct;94(4):674-681. doi: 10.1016/j.kint.2018.02.030. Epub 2018 May 24.
2
IgA nephropathy featuring massive wire loop-like deposits in two patients with alcoholic cirrhosis.两名酒精性肝硬化患者出现以大量线圈样沉积物为特征的IgA肾病。
BMC Nephrol. 2017 Dec 13;18(1):362. doi: 10.1186/s12882-017-0769-1.
3
Glomerular IgA deposition in liver disease.肝病中的肾小球IgA沉积。
Nephrol Dial Transplant. 1999 Oct;14(10):2279-82. doi: 10.1093/ndt/14.10.2279.
Zotero 插件